Sponsors (7)
Permanently authorizing priority review vouchers aims to speed availability of therapies and encourage investment for rare pediatric diseases, but it risks higher costs, program gaming, and strain on FDA review capacity that could delay other approvals.
Children with rare pediatric diseases, patients with chronic conditions, and hospitals/health systems may get eligible therapies reviewed and potentially available sooner because the priority review voucher program is made permanent, keeping the incentive and pathway for expedited FDA review in place.
Drug developers and biotech investors gain regulatory certainty and a continued financial incentive to invest in rare pediatric disease products, which could increase R&D investment into treatments for these conditions.
FDA review capacity and resource prioritization could be strained as reviewers shift attention to voucher-bearing applications, potentially delaying reviews and approvals for other products and slowing access for other patients and providers.
Taxpayers and consumers may face higher long-term costs if the voucher program results in expedited approvals based on limited evidence and leads to greater use of high-priced therapies.
Making the voucher authority permanent could encourage strategic, commercially-driven use of the program rather than focusing incentives on truly novel or highest-priority pediatric therapies, reducing the program's public-health targeting.
Based on analysis of 2 sections of legislative text.
Removes the statutory sunset so the FDA's authority to award rare pediatric disease priority review vouchers becomes permanent.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to permanently extend the authority of the Secretary of Health and Human Services to award priority review vouchers for rare pediatric disease products.
Introduced September 14, 2026 by Gus Bilirakis · Last progress September 14, 2026
Makes permanent the FDA's authority to award priority review vouchers for drugs and biologics that treat rare pediatric diseases by removing the statute's automatic expiration language. The change eliminates the previous sunset so the priority review voucher program for eligible rare pediatric disease products continues indefinitely.